INTRODUCTION {#sec1-1}
============

Toads have very large glands, and they secrete a large amount of venomous secretions with variable dose-dependent effects, this can affect other animal and human health care system.\[[@ref1][@ref2]\] The primary aim is to find substances with completely novel structures leading directly or indirectly (via a new set of lead substances) to the next generation of Pharmaceuticals with new or improved activities. Such molecules may prove to be of general or academic, biochemical and biophysical, as well as of pharmacological interest since novel molecular structures may possess previously unknown and interesting pharmacological and biochemical properties. The major source of biochemical in amphibians is in their skin gland secretions for the possible potential as an anti-diabetic. Amphibian skin is highly permeable to water and fulfills many different physicochemical functions. Most amphibians show a marked preference for damp, if not aquatic habitats, which are literally teeming with potentially pathogenic bacteria and fungi. They need to protect themselves against infection and indeed have developed a formidable array of integrated antimicrobial defense systems. Toads (*order*: *Anura*; *family*: *Bufonidae*; *genus*: *Bufo*) are distributed throughout the world, but are mainly in areas on tropical and humid temperate climates.\[[@ref3]\] Each region is characterized by presence of some species of these amphibians found in India; the most commonly found species are *Bufo melanostictus*.

Toads do not possess the venom inoculation system, but they are venomous animals, as the glands covering the whole surface of their skin secrete highly toxic venom.\[[@ref4]\] Amphibian skin glands basically consist of only two types - mucus glands and granular glands both of them are alveolar (oracinar); a third type, the tubulosaccular or alveolar glands, is confined to a small groups of frogs and have limited, specialized functions. Other types have been described in certain anuran species.\[[@ref5][@ref6]\] Bufotenin is produced from a toad is a psychoactive compound.\[[@ref7]\] Diabetes is a growing epidemic, which has been estimated to affect over 350 million people worldwide in 2011, and its prevalence is expected to increase to approximately 550 million by 2030.\[[@ref8]\] It is considered as one of the five leading causes of death in the world. It is indeed to develop more compounds with antidiabetic potential to meet the needs of the treatment of diabetes and/or diabetic complications. Exenatide (Byetta, Bydureon) is taken by injection, similar to insulin, but they're not insulin used to improve blood sugar control by mimicking the action of a hormone called glucagon-like peptide 1 and may also lead to weight loss. Byetta is a synthetic version of a protein found in the Gila monster, a poisonous lizard that lives in the Southwest and in Mexico, and this Lizard-Derived Diabetes Drug Is Approved by the Food Drug and Administration.\[[@ref9]\] In our earlier study we proved that Indian toad (*Bufomelanostictus*) paratoid gland crude secretion shown the dipeptidyl peptidase-IV (DPP-IV) inhibitory activity, these results triggered to do research on potential use of common toad parotoid gland crude extracts as antidiabetic.\[[@ref10]\]

MATERIALS AND METHODS {#sec1-2}
=====================

Animals and diet {#sec2-1}
----------------

Male Wistar rats weighing 180--220 g were used in the study. They were maintained under standard laboratory condition at ambient temperature. They were fed with pellet diet and water *ad libitum*. The protocol was approved by institutional animal ethics committee (IAEC/15/UCPSC/KU/2013) Kakatiya University, Warangal.

Drugs and chemicals {#sec2-2}
-------------------

Glimepiride (GLM) and Glibenclamide (internal standard \[IS\]) are gift samples from Chandra labs, Hyderabad, parotoid gland extract was freshly obtained by compressing the parotoid glands (it oozes out as white mass) with the help of forceps aseptically, and used in the study. Glucose estimating kits are supplied by Excel diagnostics Pvt. Ltd., Hyderabad and methanol high-performance liquid chromatography (HPLC) grade, Merck, Mumbai and diethyl ether, alloxan monohydrate is supplied by Sigma, Aldrich, and Bangalore.

Induction of diabetes in rats {#sec2-3}
-----------------------------

Diabetes was induced in rats (fasting for 12 h) by the administration of Alloxan monohydrate in ice cold normal saline at a dose of 120 mg/kg intraperitoneally.\[[@ref11]\] After 3 h 0.5 ml 10% glucose was given intraperitoneally and 5% oral glucose was given for following 24 h. After 10 days, the blood sample was collected from rats by orbital puncture of all surviving animals and the serum was analyzed for glucose levels. Rats with blood glucose levels of 250 mg/dl and above\[[@ref12]\] were considered as diabetic and selected for the study.

Pharmacokinetic and pharmacodynamic evaluation {#sec2-4}
----------------------------------------------

### Study in nondiabetic and diabetic rats {#sec3-1}

Phamacokinetic and pharmacodynamic interaction study in nondiabetic and diabetic rats. Two sets of the following animal groups (*n* = 6) are used in the study one set is for a non-diabetic group and the other set is for the diabetic group. All the parotid gland extracts, and GLM are orally given to the animals and the parotid extracts were nontoxic.

### In nondiabetic groups {#sec3-2}

Group 1 - GLM (orally 1 mg/kg)Group 2 - Parotoid gland extract in saline (Saline Parotoid Crude Extract \[SP\]-10 μg/kg) 7 days → on 8^th^ day also SPGroup 3 - Paratoid gland extract in saline (SP-10 μg/kg) 7 days → on 8^th^ day (Followed by GLM)Group 4 - Paratoid gland extract in methanol (Methonolic Parotid Extract. \[MP\]-10 μg/kg) 7 days → on 8^th^ day also MPGroup 5 - Paratoid gland extract in methanol (MP-10 μg/kg) 7 days → on 8^th^ day (followed by GLM).

### In diabetic groups {#sec3-3}

Group 1 - GLM (orally 1 mg/kg)Group 2 - Parotoid gland extract in saline (SP-10 μg/kg) 7 days → on 8^th^ day also SPGroup 3 - Paratoid gland extract in saline (SP-10 μg/kg) 7 days → on 8^th^ day (Followed by GLM)Group 4 - Paratoid gland extract in methanol (MP-10 μg/kg) 7 days → on 8^th^ day also MPGroup 5 - Paratoid gland extract in methanol (MP-10 μg/kg) 7 days → on 8^th^ day (followed by GLM).

Blood Samples were collected from orbital puncture at time intervals between 0, 0.5, 1, 2, 4, 6, 8 and 12 h using heparinized capillaries. Serum was separated by centrifugation. And blood glucose levels were determined using glucose oxidase-peroxidase method and remaining serum was stored in vials at − 70°C for pharmacokinetic parameters analysis.

### High-performance liquid chromatography description {#sec3-4}

A Shimadzu Class VP series HPLC system with two LC-10AT pumps, a SPD-10A variable wavelength programmable ultraviolet/visible detector, a SCL-10A system controller and a RP C-18 column (Merck, Hiber; 250 mm × 4.6 mm; particle size 5 μm) was used. The system was equipped with N2000 software.

### Preparation of standard graph {#sec3-5}

The stock solutions of GLM and glibenclamide were prepared in methanol at a concentration of 1 mg/ml each. Glibenclamide was used as an IS. By appropriately diluting the stock solution of GLM different concentrations (1.25, 2.5, 5, 12.5, 25, 50, 100, 125 μg/ml) and glibenclamide (100 μg/ml) were prepared. A volume of 100 μl of blank rat serum was mixed with 20 μl of 0.1N HCL, with different dilutions of 20 μl of standard GLM solution and with 20 μl glibenclamide (100 ug/ml), vortex for 5 min. Then methanol (400 μl) was added and vortexed for 5 min, and it is centrifuged at 5000 rpm for 10 min. Supernatant 1 was collected; residue was added again with methanol (400 μl) by same procedure supernatant 2 was collected and added to supernatant 1. Supernatant (1 + 2) was evaporated, and methanol (200 μl) was added to the residue, then vortexed and centrifuged. Finally, supernatant was spiked into the column. The calibration curve was obtained by plotting peak area ratio of GLM to glibenclamide (Y-axis) against GLM concentration (X-axis).

### Preparation of test samples {#sec3-6}

A volume of 100 μl of test serum was mixed with 20 μl of 0.1N HCL, with 20 μl glibenclamide (100 ug/ml), vortex for 5 min. Then methanol (400 μl) was added and vortexed for 5 min, and it is centrifuged at 5000 rpm for 10 min. Supernatant 1 was collected; residue was added again with methanol (400 μl) by same procedure supernatant 2 was collected and added to supernatant 1. Supernatant (1 + 2) was evaporated, and methanol (200 μl) was added to the residue, then vortexed and centrifuged. Finally, supernatant was spiked into the column.

### Calculation of pharmacokinetic parameters {#sec3-7}

Pharmacokinetic parameters were calculated using "KINETICA" software Adept Scientific, UK. All the data were expressed as mean ± standard deviation.

Statistical analysis {#sec2-5}
--------------------

Difference in between concentration time profiles; in between pharmacokinetic parameters; in between serum glucose levels and difference between over the entire range tested were analyzed by one-way ANOVA (Bonferroni post-test). The differences were considered to be significant at *P* \< 0.05.

RESULTS {#sec1-3}
=======

The HPLC detection of the glimepiride and glibenclamide is shown in \[[Figure 1](#F1){ref-type="fig"}\]. Both the aqueous and methanolic extracts produced better glycemic control in diabetic rats, and methanolic extract is better than the aqueous extract. Serum concentrations of GLM increased at 2^nd^ h from 8.24 ± 0.61 to 11.37 ± 1.15 and 12.5 ± 1.3 (*P* \< 0.001) with saline parotoid and methanol parotoid extracts respectively \[[Table 1](#T1){ref-type="table"}\], and the percentage glucose reduction is maximal at the 4^th^ h with both aqueous and methanolic extracts of paratoid secretions of common Indian toad \[[Table 2](#T2){ref-type="table"}\]. The saline and methanolic extracts (25%, 26% respectively) blood glucose percentage reduction activity is lesser than GLM (35%) alone, and greater than the combination with saline and methanolic extracts of parotoid gland secretions with glimepiride\[[Figure 2](#F2){ref-type="fig"}\].

![High-performance liquid chromatography chromatogram of glimepiride and glibenclamide in rat serum. Glibenclamide: Retention time-8.958 min, Glimepiride: Retention time-11.372 min](JNSBM-6-429-g001){#F1}

###### 

Mean serum concentration of GLM in presence of saline extract and methanolic extract of paratoid gland

![](JNSBM-6-429-g002)

###### 

Mean blood glucose changes and percent glucose reduction in nondiabetic group and diabetic group

![](JNSBM-6-429-g003)

![Percentage glucose reduction in diabetic group. GLM: Glimepiride; MP: Methanolic extract of Paratoid gland, SP: Saline extract of Paratoid gland](JNSBM-6-429-g004){#F2}

DISCUSSIONS {#sec1-4}
===========

The crude toad secretions are very complex structure, and they had two major groups of molecules such as biogenic amines, bufotenins, bufotionins and steroid derivatives like bufodienolides and bufotoxins.\[[@ref13][@ref14][@ref15]\] Toads of genus *Bufo* produce a highly toxic substances, they cannot inoculate these substances but can be eliminated when the glands are compressed.\[[@ref16][@ref17][@ref18]\] So far the studies have been focused on the toxic effects of the toad venom extensively,\[[@ref19][@ref20][@ref21][@ref22][@ref23][@ref24]\] but the beneficial effects of the toad venom are yet to be proved.

The chemical that is from a toad secretions is called 5-methoxy-N, N-dimethyltryptamine, and is a derivative of bufotenine, and it is an extremely potent and causes vivid hallucinations.\[[@ref25]\] Bufotoxins and other secretions from toad venom also contain other chemicals including substances that can affect the heart and mimic hormones like adrenaline. This can lead to fatal arrhythmias, such as ventricular fibrillation, as well as vasoconstriction and death.\[[@ref26]\] The toads release the substances through their skins using specialized mucous glands and secrete mucus, whereas granular glands secrete toxins. The toxins are protecting the toad from predators like birds, mammals, snakes and crocodiles.\[[@ref27][@ref28]\]

Diabetes is a chronic metabolic disorder and needs prolonged treatment for maintenance of normal blood glucose levels. Diabetes may precipitate cardiovascular, renal, neurological disorders in the long run leading to the existence of several disorders. Frog skin is considered as pharmacopeia having many potential compounds with pharmacological effects. The current study was undertaken to determine anti-diabetic potential of *Bufo* compounds derived from paratoid skin gland of toad. GLM is a known oral hypoglycemic of 3^rd^ generation sulfonyl urea. It is primarily metabolized by CYP2C9.\[[@ref29]\] Thus, the present study was planned to investigate the influence of *Bufo* compounds on the pharmacokinetics and pharmacodynamics of GLM in rat\'s *in vivo*, in both normal and alloxan induced diabetic conditions. In the study, it was evident that the paratoid gland extract has anti-diabetic potential on its own exhibiting percentage blood glucose reduction. The compound also effected pharmacodynamics of GLM relatively and pharmacokinetics of GLM after oral administration was also effected as exhibited by changes in AUMC, C~max~, t~1/2~. These results indicate that natural compound paratoid gland may inhibit the metabolism of GLM to some extent. This study leaves scope for further exploring the mechanism of action of paratoid gland extracts and also their interactions with other oral hypoglycemic agents.

CONCLUSIONS {#sec1-5}
===========

Paratoid gland secretions of the common Indian toad is anti-diabetic, in addition it has beneficial effects in combination with GLM. These secretions may inhibit the metabolism of glimepiride and may also inhibit DPP-IV activity. Further, it requires the systematic structure elucidation of the compounds and pharmacokinetic studies to explore exact mechanism of action and the beneficial effects.
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